← Oncology Approval Tracker

FDA DECISION ·

Perjeta + Herceptin Hylecta

pertuzumab + trastuzumab and hyaluronidase-oysk · Genentech

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Added subcutaneous trastuzumab and hyaluronidase-oysk as an option with pertuzumab in its existing HER2-positive settings: qualifying neoadjuvant disease, high-risk early adjuvant disease, and first-line metastatic disease with docetaxel.

LAMPGEN ANALYSIS

Why it matters

Enabled a subcutaneous trastuzumab option while retaining intravenous pertuzumab in labeled combinations.

What research teams should watch

Keep the two product routes distinct and retain HER2 testing and cardiac monitoring.

PRIMARY RECORDS

Sources